Background. Nephrotic syndrome (NS) is a clinical state characterized by massive proteinuria and excessive fluid retention. The effects of early versus late treatment with low or high doses of oral everolimus, a mammalian target of rapamycin inhibitor, on proteinuria in NS have not been previously described. Methods. The effects of early treatment (2 days prior to NS induction) versus late treatment (beginning 2 weeks following the establishment of NS) with a low (20 mg/L) or high (100 mg/L) dose of everolimus for 5-7 weeks on proteinuria and nephrin/podocin abundance were assessed in male adult SD rats with adriamycin-induced NS.
Introduction
Adriamycin (ADR)-induced nephrotic syndrome (NS) in the rat is characterized by massive proteinuria, hypoalbuminemia, dyslipidemia, hypercoagulability, edema and ascites formation [1] [2] [3] [4] . The common denominator of this experimental nephropathy, which mimics minimal-change disease, is a toxin-induced non-inflammatory glomerular foot process effacement that evolves to focal segmental glomerulosclerosis (FSGS) and tubulointerstitial injury resulting in 2231 NS [5] . It is well established that podocytes play an important role in maintaining the integrity of the glomerular filtration barrier [6] . In this context, the discovery and identification of nephrin, a transmembrane slit diaphragm protein, has improved our understanding of the molecular mechanisms involved in the maintenance and function of the glomerular filtration barrier and its role in the pathogenesis of clinical and experimental proteinuria [6] . Recently, several additional components of the slit diaphragm have been identified, including podocin, which interacts with the cytosolic tail of nephrin [7] . Disruptions in nephrin and podocin have been identified as the leading cause of several inherited and acquired forms of proteinuria [8] .
Although blockade of the renin-angiotensin-aldosterone system (RAAS), either by angiotensin-converting enzyme or angiotensin II (AT II) AT-1 receptor blockers, have been shown to be useful in reducing proteinuria and controlling renal damage in nephrotic and non-nephrotic renal diseases, its clinical efficacy is not necessarily satisfactory [9] [10] [11] [12] . Therefore, administration of various immunosuppressive regimes, containing variously steroids and cytotoxic/cytostatic drugs [cyclophosphamide, cyclosporine A (CsA), chlorambucil etc], is increasingly adopted. Since there is no final agreement regarding the anti-proteinuric efficacy of these protocols, which also vary in different disease states, and side effects are generally substantial, the clinical efficacy of newly developed immunosuppressors was evaluated [13] [14] [15] . Among these, the mammalian target of the rapamycin (mTOR) inhibitor family, which includes sirolimus and everolimus, frequently used immunosuppressant and proliferation signal inhibitors in renal transplantation [13] [14] [15] [16] [17] . Their mechanism of action is distinct from and complementary to the calcineurin inhibitors, such as CsA and tacrolimus, which have been the mainstay of therapy to prevent acute rejection after organ transplantation. However, serious side effects including renal injury and proteinuria have also been described during treatment of renal allograft nephropathy, human glomerulonephritis as well as experimental kidney disease with mTOR [15, [18] [19] [20] [21] . Despite this, mTOR inhibition has been shown to be beneficial in chronic mesangioproliferative nephropathy and to reduce proteinuria in experimental chronic anti-Thy1 nephritis and focal segmental glomerulosclerosis [22] [23] [24] . The molecular mechanisms underlying the observed beneficial or adverse responses in such treatments remain poorly elucidated. However, these differences could be attributed to the different experimental protocols, etiology of proteinuria, doses, timing of drug administration and pharmacokinetic profiles of the applied mTOR. In light of these controversial data, the aim of this study was to examine whether everolimus induces urinary protein excretion in normal rats and to explore whether various doses of this novel drug have any anti-proteinuric beneficial effects in a model of adriamycin-induced NS. In addition, the present study examines whether everolimus affects the abundance of slit diaphragm proteins, which are recognized as critically important factors in a wide variety of proteinuric disorders.
Materials and methods
Studies were conducted on male Sprague-Dawley rats, weighing~300 g. The animals were maintained in a temperature-controlled room and fed standard rat chow containing 0.5% NaCl and tap water ad libitum. All experiments were performed according to the guidelines of the Committee for the Supervision of Animal Experiments, Technion-IIT.
A-Normal rats A1-Effects of everolimus on kidney function in normal rats. This protocol was designed to evaluate whether long-term administration of everolimus (2.5 mg/kg/day for 4 weeks) induces renal injury in normal healthy rats (n ¼ 5). Animals received vehicle served as controls. Both groups were placed in individual metabolic cages for 6 days prior to treatment for daily measurements of baseline daily urinary protein excretion (UprV) and sodium excretion (U Na V), potassium excretion (UKV) and urine volume (V). Then, rats received via gavage either everolimus or vehicle and their effects on daily UprV, U Na V, U K V, V were determined for an additional 4 weeks. In addition, the effects of everolimus treatment on plasma albumin, total protein, lipid levels, blood cell counts and creatinine clearance test (CCT) were determined. During this period, mean arterial blood pressure (MAP) was measured using a tail-cuff method (IITC, Model 31, Woodland Hills, CA, USA). At the end of the treatment period, rats were anesthetized (pentobarbital, 30 mg/kg, intraperitoneally), underwent tracheostomy to prevent sudden death due to suffocation, and a polyethylene catheter (PE 50) was inserted into the left carotid artery for collection of blood samples. Blood samples were analyzed to determine the status of key biochemical and hematological parameters including creatinine, a component of the CCT formula. The kidneys were harvested for immunohistochemical determination of nephrin and podocin.
B-Nephrotic rats B1-The experimental model. NS was induced by a single dose of adriamycin (ADR) (5 mg/kg) injected into the tail vein of conscious rats according to the protocol of Bertani et al. [1] . Previously [25, 26] , we have demonstrated that ADR-induced NS in the rat is characterized by massive proteinuria, hypoalbuminemia, edema and ascites formation. Established proteinuria was observed 2 weeks following the ADR administration, resulting in death within~7 weeks.
B2-Effect of everolimus on proteinuria and kidney function in rats with NS. This protocol was designed to evaluate whether various doses of everolimus (Certican, Novartis Pharmaceuticals Inc. East Hanover, NJ) given as early or late treatment for long-term affects proteinuria in rats with NS. Rats were randomized to receive everolimus either 2 days before ADR injection (early treatment) or 3 weeks after ADR (late treatment). Rats were placed in individual metabolic cages for 5 days prior to induction of NS for measurements of baseline daily UprV, U Na V, U K V and V. On the sixth day, adriamycin was injected in to both groups to induce NS. Then, animals were returned to metabolic cages for daily monitoring of these renal parameters for an additional 5 and 7 weeks in early and late everolimus treatment, respectively. Since the effect of everolimus on proteinuria may be dose dependent, we examined the effect low (20 mg/L via drinking water, n ¼ 5) versus high (100 mg/L via drinking water, n ¼ 8) dose of the drug. The applied doses were selected based on preliminary experiments, where incremental doses of everolimus were tested in terms of immune suppression and target blood concentrations of the drug (see below). Untreated NS rats served as controls (n ¼ 11). During the treatment period, MAP was measured as described in protocol A1. At the end of the treatment period, rats from the different experimental groups were anesthetized, blood samples collected and kidneys were harvested for immunohistochemical determination of nephrin and podocin. The administration of everolimus to NS rats via drinking water rather than p.o. was chosen as it is less traumatic and prevents esophageal injury, which may affect food intake. Nevertheless, we do not exclude that this route of drug administration results in a different pharmacokinetic profile as compared with the gavage route, making the comparison of the everolimus effects on renal function/ structure between normal rats and NS animals irrelevant and was not an aim of the current study.
Immunohistochemistry
Immunofluorescence analysis of nephrin and podocin in the renal cortex was performed in the different experimental groups as well as in normal rats as described previously [25, 26] . Briefly, whole kidneys were rapidly frozen in liquid nitrogen, and 4-lm thick cryostat sections were placed on silanecoated slides and dried at room temperature. The samples were incubated with 10% normal goat serum (NGS) in phosphate-buffered saline (PBS) at room temperature for 1 h, and after that with either anti-nephrin antibodies or antibodies to podocin (Santa Cruz Biotechnology, Santa Cruz, CA) diluted 1:200 in 1% NGS in PBS for 2 h. Nephrin and podocin immunoreactivities were analyzed by measuring fluorescence intensity by digital image analysis (Image Pro, version 5, Media Cybernetics, Bethesda, MD) of images obtained by using high sensitive camera (Roper Scientific Camera, Tucson, AZ). For each rat, we analyzed 10 glomeruli from 10 different fields and the average nephrin and podocin fluorescence intensity was calculated.
Chemical analysis
The urinary concentration of protein was determined by using spectrophotometry after 3% sulfosalicylic acid precipitation of urine samples. Concentrations of creatinine in plasma and urine samples were measured by the colorimetric anthrone method. CCT was equated with the renal clearance of creatinine (Ccr ¼ GFR ¼ UcrXV/Pcr). Plasma albumin and proteins concentrations were determined using a refractometer (Biochemical laboratories, Rambam Medical Center, Haifa). Sodium concentration in plasma and urine was determined by flame photometry (model IL 943; Instrumentation Laboratories, Italy).
Statistical analysis
One-way analysis of variance (ANOVA) for repeated measures, followed by the Dunnett test, was used for comparison of treatment values with baseline value in each group. For comparison of the graphs representing control and experimental groups, two-way ANOVA was used. A value of P < 0.05 was considered statistically significant. Data are presented as mean AE SEM.
Results

A-Normal rats
A1-Plasma levels of everolimus. To assess the bioavailability of everolimus in normal rats, its circulatory levels were determined in blood samples. Mean blood concentration of everolimus was 15.9 AE 1.5 ng/mL as compared to zero levels in vehicle-treated animals. This concentration was slightly higher than the everolimus therapeutic levels in humans, which range from 3-12 ng/mL [15] . No mortality was recorded during the study.
A2.Effects of everolimus on urinary protein excretion and nephrin/podocin abundance. Figure 1 summarizes the effects of chronic treatment with everolimus on protein excretion compared with vehicle-treated animals. As shown in Figure 1A , daily administration of everolimus, even slightly above the therapeutic range, to normal rats for 4 weeks did not affect daily UprV. In fact, both UprV and cumulative protein excretion were comparable in everolimus-and vehicle-treated animals ( Figure 1B) , thus excluding renal injury. The latter conclusion is further verified by the lack of adverse effects of everolimus neither on nephrin/podocin abundance ( Figure 2 ) nor on U Na V, U K V, V, P Na , P K , CCT, P Cr , blood urea nitrogen (BUN) and MAP (Table 1) . Normal glomeruli illustrate the linear staining pattern of the slit diaphragms with anti-nephrin and antipodocin antibodies. A comparable staining pattern was observed in everolimus-treated rats (Figure 2 ). However, everolimus significantly reduced lymphocytes and platelets. In addition, the weight gain during the study period was significantly lower in the everolimus-treated animals as compared with the sham controls ( Table 1) .
B-Nephrotic rats
B1-Plasma levels of everolimus. The applied doses of the everolimus in the current protocol, namely (20 versus 100 mg/L via drinking water) increased the blood levels of the drug in NS, from 0 to 4.9 AE 0.6 and 21.3 AE 4.4 ng/mL, respectively. No mortality was recorded during the study.
B2-Effects of late versus early treatment with low or high dose of everolimus on urinary protein excretion in rats with NS. Figure 3 and Tables 2 and 3 summarize the results of chronic effects of early versus late treatment with low or high doses of everolimus on cumulative proteinuria in NS rats, as compared with untreated NS and sham controls. Administration of adriamycin induced a gradual increase in daily urinary protein excretion from 16.8 AE 2.2 to 768.5 AE 99.2 mg/day (P < 0.01) and cumulative protein excretion (from negligible values to 17556.7 AE 800.2 and 24405.9 AE 1651.0 mg (P < 0.001) during 5 and 7 weeks, respectively ( Figure 3A and B, Tables 2 and 3 ). Early administration of a low dose of everolimus to NS rats significantly reduced daily protein excretion to 613.0 AE 73.6 mg/day and cumulative proteinuria to 14257.3 AE 1512.0 mg (P < 0.05) during 5 weeks of treatment. It is evident that the line representing cumulative proteinuria of everolimus-treated NS rats significantly differs from that of untreated NS animals (P < 0.01, ANOVA 2). Similarly, late administration of a low dose of everolimus to NS rats reduced both daily and cumulative protein excretion, yet this antiproteinuric effect was smaller than that observed when the drug was given as early treatment ( Figure 3A and B, Tables  2 and 3) .
Early and late administration of a high dose of everolimus to NS rats also reduced both daily and cumulative protein excretion ( Figure 3A and B, Tables 2 and 3) . Moreover, the applied high dose of everolimus caused a severe reduction in body weight (BW) ( Table 3) , an effect that was not observed when everolimus was given at a low dose. Specifically, while untreated animals gained weight throughout the treatment period, animals treated with a late high dose of everolimus lost~20% of their basal BW after treatment (Table 3 ). In contrast, treatment with a low dose of everolimus did not reduce basal BW, on one hand and improved Hb and Hct, on the other (Tables 2 and 3 ).
B3-Effects of early versus late treatment with low or high dose of everolimus on nephrin/podocin in rats with NS. Immunofluorescence studies with antibody to nephrin or podocin in normal kidneys showed a finely dotted linear epithelial staining pattern, as has been reported by Holthofer et al. [27] and Yuan et al. [28] (Figures  4 and 5) . In contrast, the staining of glomeruli from untreated NS rats was attenuated, more dispersed and clustered. As shown in Figures 4C and D and 5C and D, semiquantitative digital image analysis revealed a reductions of fluorescence intensity of nephrin by 55-67% and of podocin by 63-69% in NS compared with sham controls, respectively. Early, and to a lesser extent late treatment, with a low dose of everolimus significantly improved nephrin and podocin immunoreactivity in NS rats (Figure 4) . In contrast, treatment with a high dose of everolimus, either early or late, was ineffective in preventing the loss of nephrin/podocin staining in NS ( Figure 5 ).
Discussion
A-Renal effects of everolimus in normal rats
The present study demonstrated that chronic administration of everolimus, at a dose of 2.5 mg/kg/day for 4 weeks to normal rats, resulted in blood levels of~16 ng/mL, which are slightly higher than those of the clinical therapeutic levels 3-12 ng/mL [15] . This dose did not produce proteinuric effects as evident in Figures 1 and 2 , suggesting that applied clinical doses of this mTOR do not induce renal injury under normal kidney function. The lack of proteinuric deleterious effects of everolimus was further supported by our finding that the abundance of nephrin and podocin, two key glomerular slit diaphragm proteins, was not affected by this immunosuppressor. Likewise, everolimus did not significantly alter glomerular filtration rate (GFR), PCr, BUN, V, PK1, PNa1, MAP or kidney and heart weight despite mild adverse effects on BW gain other than the expected suppression of the immune system as expressed by a significant decline in lymphocyte counts. Collectively, these results indicate that a therapeutic dose of everolimus lacks adverse renal and hemodynamic effects when administered to animals with normal kidney function. In contrast, when similar doses of everlomis or mTOR inhibitors were given to animals [29] [30] [31] or human beings [32, 33] with low GFR or pre-existing glomerular diseases, renal deterioration and proteinuria were documented. In this regard, Vogelbacher et al. [29] demonstrated that administration of everolimus (2.5 mg/kg/day) to rats with remnant kidney, a model of chronic renal failure, worsen the progression of the disease and induce proteinuria. According to these authors, the renal deterioration was due to the inhibitory effects of everolimus on glomerular injury repair via preventing proliferation of glomerular endothelial cells. Similarly, Daniel et al. [31] have shown that everolimus given early at high doses (1-3 mg/kg/day for a few weeks) to rats with glomerular lesions induced by antiThy1 caused adverse effects including high mortality, progressive apoptosis, crescent formation and glomerulosclerosis. Our study extends these reports by examining the effects of everolimus on nephrin and podocin, besides its effects on a wide range of biochemical and hematological parameters. The fact that everolimus did not affect the abundance of these two key proteins, which have been recognized as most specific and critically important in a wide variety of proteinuric states, strengthens the widely accepted concept that everolimus has no nephrotoxic effects under normal kidney function.
B-Renal effects of everolimus in rats with NS
The present protocol was designed to examine whether everolimus exerts anti-proteinuric effects in rats with NS and to evaluate if early pre-treatment (preventative) with this agent offers a better approach as compared with late treatment (therapeutic) in reducing the proteinuria in ADR-induced NS in rats. Aminonucleoside-induced nephropathy is widely used as an experimental model of NS with morphological similarities to minimal-change nephropathy and glomerulosclerosis and tubulointerstitial fibrosis [1] . In line with our previous findings [25, 26] , administration of adriamycin to normal rats caused a significant gradual increase in daily and cumulative protein excretion throughout the study (Figure 3) . Our results clearly demonstrate a moderate anti-proteinuric effect associated with pre-treatment with a low dose of everolimus. Similarly, late treatment with a low dose of everolimus produced, although to a lesser extent, anti-proteinuric effects in nephrotic rats. The present study extends previous reports by comparing the effects of early versus late treatment with everolimus and a low versus high dose of this drug on urinary protein excretion in experimental NS. Previously, the antiproteinuric effect of rapamycin/sirolimus, another member of the mTOR family, was described in rats with experimental membranous nephropathy induced by anti-Fx1A [30] , where it reduced the expression of the pro-inflammatory and pro-fibrotic genes including TGF-b1. Similarly, rapamycin/sirolimus (3 mg/kg/day) attenuated the severity of adriamycin-induced nephropathy in murine when given either at the time of adriamycin injection or 1 week after the induction of the NS for 6 weeks [34] , as reflected by its anti-albuminuric effects as well as preservation of renal function with only minor histological abnormalities. In line with these findings, Rangan and Coombes [35] demonstrated anti-proteinuric effects of rapamycin/sirolimus in rats with NS induced by non-immune initiated FSGS, and Daniel et al. [36] reported renoprotective effect of sirolimus in experimental mesangial proliferative glomerulonephritis. Application of the new member of mTOR, namely everolimus, as late treatment for 14 weeks was shown to attenuate proteinuria and the time course of chronic antiThy1 nephritis in the rat, via reducing the vascular endothelial growth factor and TGF-b1expression [22] . In contrast, clinical studies with sirolimus showed controversial results. While some studies reported a rapid decline in GFR with worsening proteinuria in patients with FSGS Table 3 . Summary of early versus late treatment with high dose of everolimus on various hemodynamic, biochemical and hematological parameters in nephrotic rats [18] [19] [20] [21] 37] , others showed beneficial anti-proteinuric effects [23, 24, 38] .
Unfortunately, none of the above cited studies examined the effects of mTOR inhibitors on the abundance of nephrin and podocin. The role of slit diaphragm compounds in maintaining permeable selectivity of the glomerular filtration barrier and preventing injury accompanied by proteinuria in aminonucleoside-induced NS indicates nephrin loss [39] and redistribution [39, 40] as important factors in the pathogenesis of this disease [39] [40] [41] [42] . For instance, Luimula et al. [42] demonstrated a 40 and 80% downregulation of nephrin-specific messenger RNA already at Days 3 and 10 after induction of puromycin aminonucleoside nephrosis, respectively. Similarly, clinical studies confirmed these findings in various glomerular pathologies, including NS [39, 40] . Therefore, the current study addressed this issue and demonstrated that low but not high dose of everolimus attenuated the loss of these two glomerular proteins in NS, suggesting that the anti-proteinuric effect of this agent at therapeutic dose is due to preservation of nephrin/podocin. Interestingly, high dose of everolimus also exerts anti-proteinuric effect in NS rats without preserving the nephrin/podocin integrity. However, this effect could be secondary to severe hypoalbuminemia observed in NS treated with high dose of everolimus either early or late (Tables 2 and 3 ). An additional factor that may have contributed to the anti-proteinuric effect of high dose of everolimus is the reduction in GFR in NS that were treated with the drug, especially when it was given as a late treatment. Decline in GFR is known to reduce the filtered load of protein under nephrotic conditions and subsequently, the urinary excretion of proteins. A third potential mechanism to explain the anti-proteinuric effects of everolimus in NS is an adverse effect of the drug on BW. In fact, untreated NS rats did not gain weight during the study, as compared with sham controls who exhibited an increase of~22% in their BW. It is noteworthy that rats with NS that were given high dose of everolimus as a late treatment, lost~20% of their pre-treatment BW, whereas NS rats that were subject to early everolimus administration gained only 12% BW at the end of the treatment period. The significant decrease in BW in late high-dose everolimus-treated NS rats and the attenuation of gain of BW in early high-dose everolimus-treated animals may reflect enhanced catabolic states or reduced food intake by these rats or both. The latter two suspected side effects of everolimus may reduce urinary protein excretion independently of improvement in the integrity of the glomerular barrier. It should be emphasized that the applied high dose of everolimus in this protocol resulted in drug blood levels of~20 ng/mL, which are about twice the highest therapeutic concentrations. This relatively high dose may be responsible for the loss of BW of NS rats treated with everolimus after the induction of the disease and the attenuation of weight gain in early treated NS animals. Support for this assumption derived from our findings that the therapeutic dose of everolimus did not cause BW reduction. Moreover, a few studies have reported that everolimus induces proteinuria rather than anti-proteinuria in pediatric and adult renal transplant recipients [33, 43] or in rats with chronic renal failure [29] . The distinct effects of low versus high doses of everolimus on BW, GFR and blood cell counts indicate that the obtained anti-proteinuric effects of low dose of everolimus in NS reflect a true phenomenon, rather than being secondary to undesirable adverse effects of the high dose of the drug including weight loss or hypoperfusion. Actually, the therapeutic dose of everolimus improved GFR, Hct and Hb (Table 2) , as compared with the high dose which aggravated most of these parameters besides impairing renal function. This concept is supported by other studies, where everolimus or rapamycin reduced urinary protein excretion in models of nephritis [22] and membranous nephropathy [30] , respectively. In conclusion, the present study provides new insights into the renal effects of everolimus in rats with normal kidney function and animals with nephrotic range proteinuria. Specifically, we have shown that chronic administration of everolimus at high therapeutic doses to normal rats did not induce renal injury as expressed by the lack of adverse effects on glomerular nephrin/podocin abundance. Early or late treatments of NS with therapeutic doses of everolimus reduced the proteinuria, probably via restoration of the severe decline in these key slit diaphragm proteins. However, the anti-proteinuric effects of high doses of everolimus may be secondary to the decline of GFR and the hypoalbuminemia in these rats.
